| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WDR5 |
| Uniprot No | P61964 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-334aa |
| 氨基酸序列 | ATEEKKPETEAARAQPTPSSSATQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC |
| 预测分子量 | 52.5kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural basis for the recognition of histone H3 by WDR5"**
*Couture, J.F., et al. (2006)*
解析WDR5与组蛋白H3的复合物晶体结构，揭示其WD40结构域通过精氨酸结合口袋识别H3第4位赖氨酸(K4)，为表观遗传调控机制提供结构基础。
2. **"Targeting WDR5-MYC interaction with recombinant proteins and small molecules"**
*Aho, E.R., et al. (2019)*
开发重组WDR5蛋白及小分子抑制剂，阻断其与MYC致癌蛋白的相互作用，证实抑制肿瘤细胞增殖的潜力。
3. **"Recombinant WDR5 expression and purification for biochemical studies"**
*Thomas, L.R., et al. (2018)*
优化大肠杆菌中重组WDR5的高效表达与纯化流程，验证其与组蛋白及MYC肽段的结合活性，为体外功能研究提供标准化方案。
4. **"WDR5 interacts with recombination-activating gene proteins via its N-terminal domain"**
*Guarnaccia, A.D., & Tanese, N. (2020)*
利用重组WDR5蛋白揭示其N端结构域与V(D)J重组酶RAG1/2的互作机制，提示其在免疫系统表观遗传调控中的新功能。
WDR5 (WD repeat-containing protein 5) is a conserved scaffolding protein belonging to the WD40 repeat family, characterized by its β-propeller structure formed by repeating WD40 motifs. It plays a pivotal role in epigenetic regulation, particularly as a core component of chromatin-modifying complexes. One of its best-studied roles is within the MLL/SET (mixed-lineage leukemia/Su(var)3-9. Enhancer-of-zeste, Trithorax) histone methyltransferase complexes, where it facilitates histone H3 lysine 4 methylation (H3K4me), a hallmark of transcriptionally active chromatin. By interacting with RbBP5. ASH2L, and other subunits, WDR5 stabilizes these complexes and directs their substrate specificity, influencing gene expression patterns critical for development, cell differentiation, and proliferation.
Recombinant WDR5 proteins are engineered versions expressed in heterologous systems (e.g., *E. coli* or insect cells) for biochemical and structural studies. These proteins retain the ability to bind partner proteins, nucleic acids, and small-molecule inhibitors, making them valuable tools for dissecting molecular mechanisms. For instance, recombinant WDR5 has been instrumental in identifying its role in recruiting MLL complexes to specific genomic loci and in elucidating its interaction with the WIN motif of MYC oncoproteins, linking it to cancer progression.
In drug discovery, recombinant WDR5 serves as a target for inhibitors aimed at disrupting oncogenic or disease-related pathways. Its WD40 domain’s conserved surface pockets, particularly the "WDR5-interacting" (WIN) site, are hotspots for therapeutic intervention. Studies using recombinant proteins have revealed its involvement in diseases beyond cancer, including neurological disorders and viral infection mechanisms. The accessibility of recombinant WDR5 has accelerated structural biology efforts, enabling cryo-EM and X-ray crystallography studies that inform rational drug design. Overall, recombinant WDR5 proteins bridge basic research and translational applications, offering insights into epigenetics and precision medicine strategies. (Word count: 399)
×
